These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

399 related articles for article (PubMed ID: 28619968)

  • 1. Breast Cancer Neoantigens Can Induce CD8
    Zhang X; Kim S; Hundal J; Herndon JM; Li S; Petti AA; Soysal SD; Li L; McLellan MD; Hoog J; Primeau T; Myers N; Vickery TL; Sturmoski M; Hagemann IS; Miller CA; Ellis MJ; Mardis ER; Hansen T; Fleming TP; Goedegebuure SP; Gillanders WE
    Cancer Immunol Res; 2017 Jul; 5(7):516-523. PubMed ID: 28619968
    [TBL] [Abstract][Full Text] [Related]  

  • 2. HLA class I loss in metachronous metastases prevents continuous T cell recognition of mutated neoantigens in a human melanoma model.
    Schrörs B; Lübcke S; Lennerz V; Fatho M; Bicker A; Wölfel C; Derigs P; Hankeln T; Schadendorf D; Paschen A; Wölfel T
    Oncotarget; 2017 Apr; 8(17):28312-28327. PubMed ID: 28423700
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Identification of a neoantigen epitope in a melanoma patient with good response to anti-PD-1 antibody therapy.
    Nonomura C; Otsuka M; Kondou R; Iizuka A; Miyata H; Ashizawa T; Sakura N; Yoshikawa S; Kiyohara Y; Ohshima K; Urakami K; Nagashima T; Ohnami S; Kusuhara M; Mitsuya K; Hayashi N; Nakasu Y; Mochizuki T; Yamaguchi K; Akiyama Y
    Immunol Lett; 2019 Apr; 208():52-59. PubMed ID: 30880120
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Endogenous Neoantigen-Specific CD8 T Cells Identified in Two Glioblastoma Models Using a Cancer Immunogenomics Approach.
    Johanns TM; Ward JP; Miller CA; Wilson C; Kobayashi DK; Bender D; Fu Y; Alexandrov A; Mardis ER; Artyomov MN; Schreiber RD; Dunn GP
    Cancer Immunol Res; 2016 Dec; 4(12):1007-1015. PubMed ID: 27799140
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Recognition of HLA-A2-restricted mammaglobin-A-derived epitopes by CD8+ cytotoxic T lymphocytes from breast cancer patients.
    Jaramillo A; Narayanan K; Campbell LG; Benshoff ND; Lybarger L; Hansen TH; Fleming TP; Dietz JR; Mohanakumar T
    Breast Cancer Res Treat; 2004 Nov; 88(1):29-41. PubMed ID: 15538043
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prediction and prioritization of neoantigens: integration of RNA sequencing data with whole-exome sequencing.
    Karasaki T; Nagayama K; Kuwano H; Nitadori JI; Sato M; Anraku M; Hosoi A; Matsushita H; Takazawa M; Ohara O; Nakajima J; Kakimi K
    Cancer Sci; 2017 Feb; 108(2):170-177. PubMed ID: 27960040
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Exome Sequencing to Predict Neoantigens in Melanoma.
    Pritchard AL; Burel JG; Neller MA; Hayward NK; Lopez JA; Fatho M; Lennerz V; Wölfel T; Schmidt CW
    Cancer Immunol Res; 2015 Sep; 3(9):992-8. PubMed ID: 26048577
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The neoepitope landscape of breast cancer: implications for immunotherapy.
    Narang P; Chen M; Sharma AA; Anderson KS; Wilson MA
    BMC Cancer; 2019 Mar; 19(1):200. PubMed ID: 30832597
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Apparent Lack of
    Kemps PG; Zondag TC; Steenwijk EC; Andriessen Q; Borst J; Vloemans S; Roelen DL; Voortman LM; Verdijk RM; van Noesel CJM; Cleven AHG; Hawkins C; Lang V; de Ru AH; Janssen GMC; Haasnoot GW; Franken KLMC; van Eijk R; Solleveld-Westerink N; van Wezel T; Egeler RM; Beishuizen A; van Laar JAM; Abla O; van den Bos C; van Veelen PA; van Halteren AGS
    Front Immunol; 2019; 10():3045. PubMed ID: 31998317
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Characterization of CD8
    Shinkawa T; Tokita S; Nakatsugawa M; Kikuchi Y; Kanaseki T; Torigoe T
    Oncoimmunology; 2021 Jan; 10(1):1870062. PubMed ID: 33537174
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Neoantigens elicit T cell responses in breast cancer.
    Morisaki T; Kubo M; Umebayashi M; Yew PY; Yoshimura S; Park JH; Kiyotani K; Kai M; Yamada M; Oda Y; Nakamura Y; Morisaki T; Nakamura M
    Sci Rep; 2021 Jun; 11(1):13590. PubMed ID: 34193879
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Recognition of human gastrointestinal cancer neoantigens by circulating PD-1+ lymphocytes.
    Gros A; Tran E; Parkhurst MR; Ilyas S; Pasetto A; Groh EM; Robbins PF; Yossef R; Garcia-Garijo A; Fajardo CA; Prickett TD; Jia L; Gartner JJ; Ray S; Ngo L; Wunderllich JR; Yang JC; Rosenberg SA
    J Clin Invest; 2019 Nov; 129(11):4992-5004. PubMed ID: 31609250
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The Mutation-Associated Neoantigen Functional Expansion of Specific T Cells (MANAFEST) Assay: A Sensitive Platform for Monitoring Antitumor Immunity.
    Danilova L; Anagnostou V; Caushi JX; Sidhom JW; Guo H; Chan HY; Suri P; Tam A; Zhang J; Asmar ME; Marrone KA; Naidoo J; Brahmer JR; Forde PM; Baras AS; Cope L; Velculescu VE; Pardoll DM; Housseau F; Smith KN
    Cancer Immunol Res; 2018 Aug; 6(8):888-899. PubMed ID: 29895573
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Tumor neoantigens: building a framework for personalized cancer immunotherapy.
    Gubin MM; Artyomov MN; Mardis ER; Schreiber RD
    J Clin Invest; 2015 Sep; 125(9):3413-21. PubMed ID: 26258412
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Response of established human breast tumors to vaccination with mammaglobin-A cDNA.
    Narayanan K; Jaramillo A; Benshoff ND; Campbell LG; Fleming TP; Dietz JR; Mohanakumar T
    J Natl Cancer Inst; 2004 Sep; 96(18):1388-96. PubMed ID: 15367572
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mutation position is an important determinant for predicting cancer neoantigens.
    Capietto AH; Jhunjhunwala S; Pollock SB; Lupardus P; Wong J; Hänsch L; Cevallos J; Chestnut Y; Fernandez A; Lounsbury N; Nozawa T; Singh M; Fan Z; de la Cruz CC; Phung QT; Taraborrelli L; Haley B; Lill JR; Mellman I; Bourgon R; Delamarre L
    J Exp Med; 2020 Apr; 217(4):. PubMed ID: 31940002
    [TBL] [Abstract][Full Text] [Related]  

  • 17. An immunogenic personal neoantigen vaccine for patients with melanoma.
    Ott PA; Hu Z; Keskin DB; Shukla SA; Sun J; Bozym DJ; Zhang W; Luoma A; Giobbie-Hurder A; Peter L; Chen C; Olive O; Carter TA; Li S; Lieb DJ; Eisenhaure T; Gjini E; Stevens J; Lane WJ; Javeri I; Nellaiappan K; Salazar AM; Daley H; Seaman M; Buchbinder EI; Yoon CH; Harden M; Lennon N; Gabriel S; Rodig SJ; Barouch DH; Aster JC; Getz G; Wucherpfennig K; Neuberg D; Ritz J; Lander ES; Fritsch EF; Hacohen N; Wu CJ
    Nature; 2017 Jul; 547(7662):217-221. PubMed ID: 28678778
    [TBL] [Abstract][Full Text] [Related]  

  • 18. T-cell Responses to
    Deniger DC; Pasetto A; Robbins PF; Gartner JJ; Prickett TD; Paria BC; Malekzadeh P; Jia L; Yossef R; Langhan MM; Wunderlich JR; Danforth DN; Somerville RPT; Rosenberg SA
    Clin Cancer Res; 2018 Nov; 24(22):5562-5573. PubMed ID: 29853601
    [No Abstract]   [Full Text] [Related]  

  • 19. A novel HLA-A2-restricted CTL epitope of tumor-associated antigen L6 can inhibit tumor growth in vivo.
    Tu SH; Huang HI; Lin SI; Liu HY; Sher YP; Chiang SK; Chong P; Roffler S; Tseng GC; Chen HW; Liu SJ
    J Immunother; 2012 Apr; 35(3):235-44. PubMed ID: 22421941
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dominant neoantigen verification in hepatocellular carcinoma by a single-plasmid system coexpressing patient HLA and antigen.
    Chen P; Chen D; Bu D; Gao J; Qin W; Deng K; Ren L; She S; Xu W; Yang Y; Xie X; Liao W; Chen H
    J Immunother Cancer; 2023 Apr; 11(4):. PubMed ID: 37076248
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.